Comparative study of the sustained erythropoiesis-stimulating agents in patients with chronic kidney disease at predialysis stage

Comparative study of the sustained erythropoiesis-stimulating agents in patients with chronic kidney disease at predialysis stage - Comparative study of the sustained ESA in patients with CKD at prdialysis stage

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000008531

Enrollment

Registered

2013-12-31

Start date

2012-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic kidney disease

Interventions

darbepoetin CERA

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patients who receive subcutaneous administration of darbepoetin once in four weeks more than 24 weeks The patients whom Hb level of most recent 12 weeks is maintained over 9.5 g/dL The patients whom darbepoetin dosage of most recent 12 weeks is stable The patients whom ferritin level at study initiation is over 80 ng/mL

Exclusion criteria

Exclusion criteria: The patients who received transfusion within the past 24 weeks The patients who refused subcutaneous injection

Design outcomes

Primary

Measure	Time frame
Maintenance rate of traget Hb at weeks 24 and 48 Change rate of eGFR at weeks 24 and 48	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026